| Vial Size |
25 mg , 50 mg |
|---|
Avanafil (≥98%) - 50 mg vial
$114.00 / vial
Linagliptin (≥98%)
$80.00 – $144.00 / vial
| Product Name | Linagliptin analytical standard |
| Synonym | Tradjenta, B1 1356BS, 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione |
| Product Nawah code | AMAH21124 |
| CAS number | 668270-12-0 |
| Empirical Formula | C25H28N8O2 |
| Molecular weight | 472.54g/mol |
| PubChem Substance ID | 10096344 |
| Storage temperature | 2-8 oC , Dark |
| Physical appearance | White powder |
| Purity | ≥98% |
| Description | Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise |
| Related literature | DrugBank: URL: https://www.drugbank.ca/drugs/DB08882
|
Additional information
Reviews
There are no reviews yet.